Search Results - roger+lo

6 Results

Sort By:

Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)

UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...

Published: 11/4/2024 | Inventor(s): Roger Lo

Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)

UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....

Published: 5/8/2024 | Inventor(s): Roger Lo

Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

2022-077 Methods to Enhance Cancer Immune Surveillance and Therapeutic Efficacy in Melanoma by Control of Cancer Cell-Surface PD-L1/L2 and the E3 Ligase Itch

SUMMARY: UCLA researchers in the Department of Medicine have discovered an enzyme that downregulates tumor expression levels of PD-L1/L2 in MAPKi-resistant melanoma with the potential to enhance cancer immune surveillance and therapeutic efficacy in drug-resistant melanoma. TITLE: Methods to enhance cancer immune surveillance and therapeutic efficacy...

Published: 9/7/2023 | Inventor(s): Roger Lo

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

2022-021 Methods to Enhance the Efficacy of Combined Targeting of Immune Checkpoint and MAPK Pathways

SUMMARY: Researchers from UCLA’s David Geffen School of Medicine have discovered a novel regimen using MAPK inhibition and immune checkpoint therapy for the treatment of melanoma and other cancers. Furthermore, they have outlined cellular targets in the tumor microenvironment with key roles in improving sensitivity to therapy. BACKGROUND: Programmed...

Published: 7/19/2023 | Inventor(s): Roger Lo

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

2022-187 Blocking Chromothriptic Genomic Instability to Prevent the Evolution of MAPK Inhibitor Resistance in Melanoma

SUMMARY: UCLA researchers in the Department of Medicine have developed a novel therapeutic method to prevent acquired resistance to MAPK drug inhibition in melanoma. BACKGROUND:Melanoma is the fifth most common cancer in the United States and the most fatal of all skin cancer types. Typical treatments of melanoma tumors include pharmacological drugs...

Published: 9/7/2023 | Inventor(s): Roger Lo

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology

Methods for Predicting Response Patterns to Anti-PD-1 Therapy in Metastatic Melanoma (UCLA Case No. 2016-582)

SUMMARYDr. Roger Lo and colleagues in the Department of Medicine at UCLA have identified a method to predict a melanoma patient’s resistance to pembrolizumab and other immune checkpoint inhibitors.BACKGROUNDImmune checkpoint inhibitors are the most recent stars in cancer therapeutics: the first 4+ drugs in the category have received breakthrough...

Published: 2/14/2024 | Inventor(s): Roger Lo, Antoni Ribas, Willy Hugo, Jesse Zaretsky

Keywords(s):

Category(s): Diagnostic Markers, Therapeutics > Oncology > Oncology Immunotherapy